Celgene - ABRAXANE + Pipeline Drugs = Long Term Growth!
Despite setback to Revlimid’s label expansion in 1st line RRMM and as maintenance therapy in EU, Celgene (CELG) 3Q12 earnings highlighted growth of Revlimid globally on both a YoY and sequential basis. We do not see risk to Revlimid’s growth for at least the next 4 years and expect double digit sales CAGR, healthy cash flow and approval of new products (Pomalidomide, Apremilast, label expansion of ABRAXANE). Should ongoing PhIII studies of Revlimid - MM-015 (NDDMM & maintenance), IFM 2009-05 (Post-ASCT maintenance), MM-020 FIRST (NDMM) and CALGB 100104 (Post-ASCT maintenance) demonstrate significant OS and no further increase in malignances, EU approval may also come by 2014. Positive data from ABRAXANE trials in melanoma and pancreatic cancer……please read our report released on 11th Nov. 2012, titled, 'ABRAXANE + Pipeline Drugs = Long Term Growth!'
